Updated:
R3 Bio
R3 Bio is a multi-family office focused on life sciences, with offices in Pasadena, Montreal, and other North American biotech hubs.
R3 Bio
R3 Bio is a multi-family office headquartered in Pasadena, California, with additional offices in Montreal, Short Hills, San Francisco, and Cambridge. The firm focuses on life sciences and biotechnology, investing in companies that bridge preclinical research and clinical-stage development. R3 Bio's strategy spans venture-stage biotech, therapeutics, diagnostics, and healthcare services. The firm makes direct investments and co-investments alongside institutional partners. Known portfolio companies include names such as Translate Bio (acquired by Sanofi in 2021) and Moderna (publicly traded mRNA therapeutics platform). The geographic footprint covers the United States and Canada, with a bias toward innovation hubs. The firm's team size and total AUM remain undisclosed. R3 Bio maintains a multi-city presence to access deal flow from leading research universities and biotech clusters. No recent operational events have been publicly reported in the past 24 months. R3 Bio's structural differentiator is its multi-family office model focused exclusively on life sciences, a narrow mandate that allows deep domain expertise. This contrasts with generalist family offices that diversify across sectors.
General information
Firm type
Multi Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pasadena
Corporate office
Pasadena, CA, United States
Additional offices
Montreal, Canada · Short Hills, NJ, United States · San Francisco, CA, United States · Cambridge, MA, United States
Sector focus
Frequently asked questions
What does R3 Bio invest in?
R3 Bio focuses on life sciences and biotechnology, including therapeutics, diagnostics, and healthcare services. The firm invests across early-stage venture and clinical-stage opportunities, often co-investing with institutional partners (per public record).
Where is R3 Bio based?
R3 Bio's primary office is in Pasadena, California, with additional offices in Montreal, Canada; Short Hills, New Jersey; San Francisco, California; and Cambridge, Massachusetts (public record).
Is R3 Bio a single-family office or multi-family office?
Based on its multiple office locations and investment structure, R3 Bio is categorized as a multi-family office serving several wealthy families, though the specific principals and wealth origins are not publicly disclosed.
Does R3 Bio make direct investments?
Yes, R3 Bio makes direct investments in biotech companies. The firm also engages in co-investments alongside other institutional investors, as seen in its involvement with companies such as Translate Bio and Moderna (per SEC filings and press releases).
What stages does R3 Bio target?
R3 Bio appears to target early-stage venture through clinical-stage life sciences companies. Its portfolio includes both private preclinical firms and publicly traded biotechnology platforms (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: